News Headlines Article

‘Cancer vaccine’ startup Gritstone ascends with $100M round
San Francisco Business Times

An East Bay biotech startup will use a $102 million venture capital investment to anchor its climb toward cancer’s latest, greatest summit. Gritstone Oncology Inc. aims to develop “cancer vaccines” that can be adapted to specific patients at specific times by targeting so-called tumor-specific neoantigens, or new, unique amino acid tags that emerge as cancer cells mutate. The startup initially well set up shop in Emeryville and Cambridge, Mass., and will be led by co-founder, president and CEO Dr. Andrew Allen, the former chief medical officer at Clovis Oncology Inc.